REFERENCES

The following publications That involved the clinical use of the investigational new drug Flornaptitril F-18 were through institutionally-approved IRB protocols

UCLA

UCLA study first to image concussion-related abnormal brain proteins in retired players

PET Imaging of Neuropathology

PET imaging of neuropathology in tauopathies: progressive supranuclear palsy

Neuroimaging

Neuroimaging of amyloids and relationships of electronic structures and geometries to binding affinities

Amyloid and Tau

PET of brain amyloid and tau in mild cognitive impairment

Self-Reported Memory Impairment

Self-reported memory impairment and brain PET of amyloid and tau

Automated Analysis

Automated analysis in FDDNP PET: Validation through the classification of Alzheimer's disease patients

FDDNP-PET and Alzheimer's Disease

The merits of FDDNP-PET imaging in Alzheimer's disease

Postmortem 3-D Brain

Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging

Voxel-Based Analysis

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG

[F-18]FDDNP microPET Imaging

correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: Effects of aging, in vivo blockade, and anti-Aβ antibody treatment

Cognitive Status

Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia

Our State of the Science

Learn more

CereMark’s products are in various stages of pre-clinical and clinical investigational new drug studies and are not yet approved for human use.

© All rights reserved